首页> 外文OA文献 >FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

【2h】

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

机译：FDA对帕尔巴昔米菌的批准结合氟斯特语进行治疗激素受体阳性，HER2阴性转移性乳腺癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Amanda J. Walker; Suparna Wedam; Laleh Amiri-Kordestani; Erik Bloomquist; Shengui Tang; Rajeshwari Sridhara; Wei Chen; Todd R. Palmby; Jeanne Fourie Zirkelbach; Wentao Fu; Qi Liu; Amy Tilley; Geoffrey Kim; Paul G. Kluetz; Amy E. McKee; Richard Pazdur;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer [J] . Walker Amanda J., Wedam Suparna, Amiri-Kordestani Laleh, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第20期

机译：FDA批准Palbociclib与Fulvestrant联合用于激素受体阳性，HER2阴性转移性乳腺癌的治疗
2. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer [J] . Ama J. Walker, Suparna Wedam, Laleh Amiri-Kordestani, Cancer reviews . 2016,第Nova期

机译：FDA对帕尔巴昔米菌的批准结合氟斯特语进行治疗激素受体阳性，HER2阴性转移性乳腺癌
3. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 425, 2016) [J] . Cristofanilli M., Turner N. C., Bondarenko I The lancet oncology . 2016,第4期

机译：Fulvestrant加palbociclib与fulvestrant加安慰剂治疗先前接受内分泌治疗（PALOMA-3）进展的激素受体阳性，HER2阴性转移性乳腺癌：多中心，双盲，3期随机对照试验的最终分析（第17卷，第425页，2016年）
4. Polymer-Drug Conjugates as platforms for combination therapy in the treatment of hormone-dependent breast cancer [C] . C. Deladriere. E. Masia, F. Greco, R. Lucas, Annual meeting exposition of the Controlled Release Society . 2011

机译：聚合物-药物结合物可作为联合疗法治疗激素依赖性乳腺癌的平台
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter Randomized Placebo-Controlled Phase III Study (PALOMA-3) [O] . Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, 2016

机译：激素受体阳性/ HER2阴性晚期转移性乳腺癌妇女中的Palbociclib与氟维西汀合用：来自多中心随机安慰剂对照的III期研究的详细安全性分析（PALOMA-3）
7. Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer [O] . McGahan L. 2017

机译：Palbociclib（Ibrance®）与氟维司群合用，用于治疗激素受体阳性，HER2阴性的晚期或转移性乳腺癌

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

著录项

相似文献

相关主题

期刊订阅